No headlines found.
Globe Newswire (Wed, 20-Mar 8:00 AM ET)
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
Globe Newswire (Thu, 7-Mar 4:01 PM ET)
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
Globe Newswire (Mon, 26-Feb 9:00 AM ET)
Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference
Globe Newswire (Mon, 5-Feb 4:05 PM ET)
Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer
Globe Newswire (Thu, 4-Jan 4:05 PM ET)
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
Lumos Pharma trades on the NASDAQ stock market under the symbol LUMO.
As of March 28, 2024, LUMO stock price climbed to $2.86 with 203 million shares trading.
LUMO has a beta of 0.31, meaning it tends to be less sensitive to market movements. LUMO has a correlation of 0.00 to the broad based SPY ETF.
LUMO has a market cap of $23.19 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, LUMO stock traded as high as $13.59 and as low as $2.51.
The top ETF exchange traded funds that LUMO belongs to (by Net Assets): VTI, VXF, DFAC, DFUS, DCOR.
LUMO has underperformed the market in the last year with a price return of -12.0% while the SPY ETF gained +33.7%. LUMO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -7.7% and -3.7%, respectively, while the SPY returned +10.1% and +1.7%, respectively.
LUMO support price is $2.66 and resistance is $2.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LUMO stock will trade within this expected range on the day.